Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Stroke is a major cause of adult disability. Currently approved reperfusion therapies are
provided to only a small percentage of patients in the U.S. New therapies are needed that
improve outcome and that can be accessed by a majority of patients. Animal studies suggest
that bone marrow-derived mesenchymal stem cells, administered intravenously days after a
stroke, safely improve long-term behavioral outcome. A large human experience suggests the
safety of allogeneic bone marrow-derived mesenchymal stem cells. The current study aims to
assess the safety of this therapy in patients with recent ischemic stroke.